Constraints to counting bioluminescence producing cells by a commonly used transgene promoter and its implications for experimental design.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
05 08 2019
Historique:
received: 20 09 2017
accepted: 02 07 2019
entrez: 7 8 2019
pubmed: 7 8 2019
medline: 24 10 2020
Statut: epublish

Résumé

It is routine to genetically modify cells to express fluorescent or bioluminescent reporter proteins to enable tracking or quantification of cells in vitro and in vivo. Herein, we characterized the stability of luciferase reporter systems in C4-2B prostate cancer cells in mono-culture and in co-culture with bone marrow-derived mesenchymal stem/stromal cells (BMSC). An assumption made when employing the luciferase reporter is that the luciferase expressing cell number and bioluminescence signal are linearly proportional. We observed instances where luciferase expression was significantly upregulated in C4-2B cell populations when co-cultured with BMSC, resulting in a significant disconnect between bioluminescence signal and cell number. We subsequently characterized luciferase reporter stability in a second C4-2B reporter cell line, and six other cancer cell lines. All but the single C4-2B reporter cell population had stable luciferase reporter expression in mono-culture and BMSC co-culture. Whole-genome sequencing revealed that relative number of luciferase gene insertions per genome in the unstable C4-2B reporter cell population was lesser than stable C4-2B, PC3 and MD-MBA-231 luciferase reporter cell lines. We reasoned that the low luciferase gene copy number and genome insertion locations likely contributed to the reporter gene expression being exquisitely sensitive BMSC paracrine signals. In this study, we show that it is possible to generate a range of stable and reliable luciferase reporter prostate- and breast- cancer cell populations but advise not to assume stability across different culture conditions. Reporter stability should be validated, on a case-by-case basis, for each cell line and culture condition.

Identifiants

pubmed: 31383876
doi: 10.1038/s41598-019-46916-z
pii: 10.1038/s41598-019-46916-z
pmc: PMC6683182
doi:

Substances chimiques

Luminescent Proteins 0
Luciferases EC 1.13.12.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11334

Références

Int J Cancer. 2011 May 1;128(9):2182-91
pubmed: 20617516
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
J Biomol Tech. 2008 Dec;19(5):342-7
pubmed: 19183798
BMC Cancer. 2015 Nov 06;15:864
pubmed: 26545722
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
J Biomed Opt. 2011 Apr;16(4):047003
pubmed: 21529093
Biotechniques. 2003 Nov;35(5):1022-6, 1028-30
pubmed: 14628676
Cell Tissue Res. 2015 Sep;361(3):755-68
pubmed: 25924853
Cell Transplant. 2010;19(1):29-42
pubmed: 19878627
Prostate. 2012 Sep 1;72(12):1317-27
pubmed: 22213130
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Mol Cancer. 2017 Feb 1;16(1):31
pubmed: 28148268
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14342-6
pubmed: 18794521
Int J Cancer. 1994 May 1;57(3):406-12
pubmed: 8169003
Nat Rev Clin Oncol. 2011 Sep 27;8(11):677-88
pubmed: 21946842
J Hematol Oncol. 2013 Jan 23;6:10
pubmed: 23343252
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W71-4
pubmed: 17485472
PLoS One. 2010 Feb 23;5(2):e9364
pubmed: 20186331
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell Stem Cell. 2011 Jul 8;9(1):11-5
pubmed: 21726829
Cancer Res. 1994 May 15;54(10):2577-81
pubmed: 8168083
Nat Med. 2010 Apr;16(4):483-9
pubmed: 20228816
J Natl Cancer Inst. 1974 Sep;53(3):661-74
pubmed: 4412247
Genome Res. 2009 Sep;19(9):1639-45
pubmed: 19541911
BMC Cancer. 2003 Apr 24;3:13
pubmed: 12713671
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
J Biol Methods. 2015;2(1):
pubmed: 26146646
Blood. 2012 Apr 12;119(15):e131-8
pubmed: 22289890
Gene. 2001 Jul 11;272(1-2):149-56
pubmed: 11470520
BMC Bioinformatics. 2012 Jun 18;13:134
pubmed: 22708584
Anticancer Res. 2002 Nov-Dec;22(6A):3325-30
pubmed: 12530082
Biomaterials. 2015 Sep;62:1-12
pubmed: 26010218
Phys Med Biol. 2007 Apr 21;52(8):2035-54
pubmed: 17404454
Mol Imaging Biol. 2011 Feb;13(1):43-52
pubmed: 20396957
J Transl Med. 2014 Oct 04;12:278
pubmed: 25280402
Biochem Biophys Res Commun. 2010 Nov 12;402(2):228-34
pubmed: 20933502

Auteurs

E O Mosaad (EO)

School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.
Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Translational Research Institute, Brisbane, Australia.
Biochemistry Division, Chemistry Department, Faculty of Science, Damietta University, Damietta, Egypt.

K Futrega (K)

School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.

I Seim (I)

Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Translational Research Institute, Brisbane, Australia.
Comparative and Endocrine Biology Laboratory, Translational Research Institute-Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia.
Integrative Biology Laboratory, College of Life Sciences, Nanjing Normal University, Nanjing, China.

B Gloss (B)

Garvan Institute of Medical Research, Sydney, Australia.

K F Chambers (KF)

Quadram Institute Bioscience, Norwich Research Park, Norwich, UK.

J A Clements (JA)

Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Translational Research Institute, Brisbane, Australia.

M R Doran (MR)

School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia. michael.doran@qut.edu.au.
Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Translational Research Institute, Brisbane, Australia. michael.doran@qut.edu.au.
Mater Medical Research - University of Queensland, Translational Research Institute (TRI), Brisbane, Australia. michael.doran@qut.edu.au.
Australian National Centre for the Public Awareness of Science, Australian National University, Canberra, Australia. michael.doran@qut.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH